History
  • No items yet
midpage
Henry v. Angelini Pharms, Inc.
2:17-cv-02593
E.D. Cal.
Mar 31, 2020
Read the full case

Background

  • Plaintiff Toby Henry, a California resident, took a 50 mg dose of generic trazodone in California in 2015 and alleges he developed priapism and resulting permanent impotence.
  • Plaintiff sued Teva (generic manufacturer) and Angelini Pharma and Endo Ventures (brand/Oleptro NDA holders or successors) asserting strict liability, negligence, warranty, negligent misrepresentation, negligence per se, and punitive damages based on allegedly inadequate priapism warnings.
  • Plaintiff alleges Oleptro once carried a prominent priapism warning that was later diminished (circa 2012), and that generic manufacturers (including Teva) adopted Oleptro’s weaker labeling.
  • Plaintiff asserts Angelini and Endo had contacts with California through marketing/distribution (including an alleged salesman, Scot Van Steenburg, who marketed Oleptro in Los Angeles in 2010–2011).
  • Defendants moved to dismiss for lack of personal jurisdiction (Rule 12(b)(2)); Plaintiff sought in the alternative a transfer to Maryland under 28 U.S.C. § 1631. Plaintiff also moved to strike Angelini’s reply; the court denied that motion as moot.

Issues

Issue Plaintiff's Argument Defendant's Argument Held
General jurisdiction Angelini and Endo do sufficient continuous business in California to be "at home." Neither is at home in California; incorporation/principal place control; shipments/marketing alone insufficient. Dismissal — no general jurisdiction; plaintiffs offered no showing contacts were so "substantial and of such a nature" to render defendants at home.
Specific jurisdiction California is related because defendants marketed Oleptro in California and their conduct (labeling) foreseeably affected generics causing injury here; adduces Van Steenburg’s California sales activity. Contacts are too attenuated: plaintiff was injured by Teva’s generic in CA, not by defendants; any marketing in CA (2010–2011) is speculative and unrelated to Teva’s later labeling. Dismissal — no specific jurisdiction; plaintiff failed to show claims arose out of defendants’ forum activities; allegations (LinkedIn-based) were speculative and untethered.
Transfer under 28 U.S.C. § 1631 If jurisdiction lacking, transfer to Maryland is appropriate in interest of justice (statute of limitations concerns; Angelini’s principal place in Maryland). Transfer is improper because transferee must have jurisdiction over all defendants; Maryland may not have jurisdiction over Teva and Endo based only on FDA filings. Denied — transfer not in interest of justice; unclear Maryland jurisdiction over all defendants and transfer would spawn duplicative litigation.
Motion to strike Angelini’s reply Reply exceeded page limits; should be struck. Procedural challenge improper basis and would not affect outcome. Denied as moot — court ignored the reply and reached same result without considering it.

Key Cases Cited

  • International Shoe Co. v. Washington, 326 U.S. 310 (established minimum-contacts due process test)
  • Goodyear Dunlop Tires Operations, S.A. v. Brown, 564 U.S. 915 (general jurisdiction requires affiliations rendering corporation at home)
  • Daimler AG v. Bauman, 571 U.S. 117 (corporation ordinarily at home only in state of incorporation or principal place)
  • Schwarzenegger v. Fred Martin Motor Co., 374 F.3d 797 (prima facie showing of jurisdiction on written record)
  • Roth v. Garcia Marquez, 942 F.2d 617 (Ninth Circuit three-part specific-jurisdiction test)
  • In re W. States Wholesale Nat. Gas Antitrust Litig., 715 F.3d 716 (plaintiff’s burden to establish personal jurisdiction)
  • Zeneca Ltd. v. Mylan Pharm., Inc., 173 F.3d 829 (ANDA filings to FDA are government contacts; not basis for state personal jurisdiction)
  • Acorda Therapeutics, Inc. v. Mylan Pharms., 817 F.3d 755 (in patent context, ANDA filing may be tied to in-state sales and support jurisdiction)
  • Cruz-Aguilera v. I.N.S., 245 F.3d 1070 (factors for deciding transfer under § 1631)
  • Rodriguez-Roman v. INS, 98 F.3d 416 (requirements for transfer under § 1631)
  • Shapiro v. Bonanza Hotel Co., 185 F.2d 777 (transferee court must have jurisdiction, venue, and amenability to service)
  • Mavrix Photo, LLC v. LiveJournal, Inc., 647 F.3d 1213 (burden shifts to defendant to show unreasonableness if plaintiff meets first two jurisdictional prongs)
  • Love v. Associated Newspapers, Ltd., 611 F.3d 601 (California long-arm statute coextensive with federal due process)
Read the full case

Case Details

Case Name: Henry v. Angelini Pharms, Inc.
Court Name: District Court, E.D. California
Date Published: Mar 31, 2020
Docket Number: 2:17-cv-02593
Court Abbreviation: E.D. Cal.